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Mikael Jondal,* Reinhold Schirmbeck,† reactivity in F1 (A 3 B) hosts. Although the mode of
transfer of antigenic material from the transplanted, im-and Jo¨rg Reimann†
munogenic cells to host-derived APCduring cross-prim-*Microbiology and Tumor Biology Center
ing has not been elucidated, recent evidence for theKarolinska Institute
shedding of antigenic vesicles (Zhou et al., 1992a; Ra-S-171 77 Stockholm
poso et al., 1996) and for the release of immunogenic,Sweden
apoptotic blebs (Casciola-Rosen et al., 1996) provides†Institute of Medical Microbiology
interesting possibilities for antigen transfer to APC. Hu-University of Ulm
ang et al. (1996b) recently studied cross-priming usingD-89069 Ulm
influenza virus nucleoprotein–transfected H-2d tumorFederal Republic of Germany
cells given to irradiated H-2dxb mice rescued with bone
marrow from TAP2/2 H-2b mice. These mice developed
a normal T cell compartment (on the TAP1/1 thymic epi-Introduction
thelial cells), which, however, could not respond to theDifferent processing pathways operate for major histo-
nucleoprotein-transfected tumor cells, demonstrating acompatibility complex (MHC)-restricted peptide presen-
TAP dependency of the cross-priming effect. Whethertation of exogenous and endogenous antigens (Tow-
the TAP dependency reflected processing of the antigennsend and Bodmer, 1989; Brodsky and Guagliardi, 1991;
in the classical cytosolic class I pathway or a reducedYewdell and Bennink, 1992; Germain and Margulies,
amount of class I in an alternative processing compart-1993). Exogenous antigens are internalized by antigen-
ment was not determined.presenting cells (APC) and degraded at an acid pH in
Injection of inactivated, noninfectious virus particlesvesicular intracellular compartments. Generated pep-
primes CTL responses, although higher doses thantides are then loaded onto MHC class II (MHC-II) mole-
those used with the respective infectious, replicatingcules and presented at the cell surface to CD41 helper
virus are required. Association of exogenous antigensT cells. In the cytoplasm, peptides are generated from
with some adjuvants, e.g., immune-stimulating com-endogenous antigens by degradation involving a multi-
plexes (ISCOMs), liposomes, squalene, or saponin, en-catalytic proteinase complex, the proteasome. Cyto-
hances their immunogenicity for CTL precursors. CTL
solic peptides are transported into the endoplasmic re-
responses are efficiently primed by the injection of pro-
ticulum (ER) lumen by ATP-dependent transporters
tein antigens complexed with heat shock proteins (hsp).
associated with antigen presentation (TAPs). In the ER
CTL priming by the injection of large, particulate anti-
lumen, peptides bind to nascent MHC class I (MHC-I)
gens such as recombinant bacteria, crude cell lysates,
molecules in a chaperone-assisted assembly that gen-
denatured aggregates, and antigen-coupled beads, has
erates stable trimeric MHC-I heavy chain–b2-microglob- been described. Immunogenicity of exogenous proteins
ulin–peptide complexes. These transport- and presenta-
for CTL is also strikingly increased by denaturation of
tion-competent complexes move to the cell surface for
protein antigenswith anionic detergents. Some covalent
recognition and activation of CD81 cytotoxic T lympho-
modifications of proteins (lipid conjugation, cationiza-
cytes (CTL). This clear-cut dichotomy between an
tion) convert them into potent inducers of CTL immunity.
exogenous processing pathway for MHC-II-restricted T Multimeric virus-like particles assembled from surface
cell response and an endogenous pathway for MHC-I- or core viral proteins are surprisingly effective in stimu-
restricted T cell response is supported by extensive lating MHC-I-restricted CTL when injected at low doses
experimental data. However, recent data show that the without adjuvants. Synthetic peptides, corresponding
injection of various types of exogenous antigens effi- to immunodominant epitopes, generate strong CTL re-
ciently prime MHC-I-restricted CTL responses. Here, we sponses in vivo when given in isolation, mixed with adju-
briefly summarize these findings and discuss potential vants, or covalently or noncovalently associated with
uptake mechanisms and processing pathways for exog- lipid carriers.
enous antigens. Although little is yet known about alter- An important issue is the subcellular handling of these
native MHC-I processing pathways in APC, evidence for modified antigens after internalization into APC. Are all
phagocytic and nonphagocytic processing pathways is of these eventually transferred to the cytosolic compart-
emerging. ment for conventional MHC-I processing, or does pro-
cessing occur in alternative compartments? In eukaryo-
Exogenous Antigens That Prime tic cells, there is proteolytic activity in the cytosol, on
MHC-I-Restricted CTL the cell surface (e.g., ectopeptidases CD10, CD13, and
Although injection of soluble proteins does not generate CD26), and invesicular compartments like the ER lumen,
CTL responses in general, a growing number of modified endosomes, and lysosomes (Dice and Terlecky, 1994;
exogenous protein antigens prime MHC-I-restricted Authier et al., 1994; Ciechanover and Schwartz, 1994;
CTL responses (see references in Table 1). Virus- Bonifacino and Klausner, 1994). Peptide processing for
infected cells, cells expressing minor histocompatibility MHC-II presentation has been shown to occur at the
antigens, and tumor cells can cross-prime MHC-I- cell surface; in a special lysosome-like compartment
restricted antigen-specific CTL, i.e., the transfer of anti- (MIIC or CIIV) containing newly synthesized MHC-II mol-
ecules; in early endosomes recruiting MHC-II moleculesgen-bearing donor A cells generates B-restricted CTL
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Table 1. Exogenous Antigen Preparations That Prime MHC-I-Restricted T Cell Responses In Vivo
Antigen Formulations Antigen System References
Cross-priming Minor H antigen Bevan, 1976a, 1976b; Knowles et al., 1979
Viral antigen (SV40 T-Ag) Huang et al., 1994, 1996a, 1996b
Tumor-associated antigens
Inactivated virus Cytomegalovirus Reddehase et al., 1984; Liu et al., 1995
Sendai virus
ISCOM-associated HIV gp120 Takahashi et al., 1990; Heeg et al., 1991
Ovalbumin van Binnendijk et al., 1992
Measles virus
Liposome-associated Various protein antigens Collins et al., 1992; Huang et al., 1992
Lopes and Chain, 1992; Miller et al., 1992
Nair et al., 1992, 1992b; Reddy et al., 1992
Zhou et al., 1992a, 1992b; Chen et al., 1993
Squalene HIV gp120 Raychaudhuri et al., 1992
Saponin HIV gp120 Wu et al., 1992, 1994
Ovalbumin Newman et al., 1992
hsp-complexed Tumor-associated antigen Li and Srivastava, 1993; Srivastava et al.,
1994; Srivastava, 1993; Undono et al., 1994
Undono and Srivastava, 1993, 1994
(Recombinant) bacteria Various protein antigens Aggarwal et al., 1990; Kaleab et al., 1990
Aldovini and Young, 1991; Stover et al.,
1991, 1993; Schafer et al., 1992; Denkers et
al., 1993; Pfeifer et al., 1993a, 1993b; Yasutomi et
al., 1993a; Harding and Song, 1994; Szalay
et al., 1994
Parasites da Conceicao Silva et al., 1994
Denkers et al., 1993
Denatured aggregates Surface antigen of HBV Schirmbeck et al., 1995a
Antigen-coupled beads Ovalbumin Kovacsovics-Bankowski et al., 1993; Rock et
al., 1993; Norbury et al., 1995
Denatured protein Ovalbumin Staerz et al., 1987; Schirmbeck et al., 1994a
antigens HIV gp160 Doe et al., 1994; Schirmbeck et al., 1995b
LCMV proteins Bachmann et al., 1994; Weidt et al., 1994
Influenza virus proteins Yamada et al., 1985; Wraith et al., 1987; Wraith and
SV40 T-antigen Vessey, 1986; Tevethia et al., 1980; Schirmbeck et
Malaria CS protein al., 1992, 1993; Suss and Pink, 1992
Surface protein of HBV Schirmbeck et al., 1994c; Ulmer et al., 1994
Pseudomonas exotoxin
Lipid conjugation Peptide vaccines Deres et al., 1989; Schild et al., 1991a, 1991b
Martinon et al., 1992; Nardelli and Tam,
1993; Vitiello et al., 1995
Multimeric protein Yeast Ty particles Harris et al., 1992; Layton et al., 1993
particles HIV gag particles Schirmbeck et al., 1995b; Griffiths et al.,
Surface particles of HBV 1993; Schirmbeck et al., 1994b, 1994d
Synthetic peptides Alchele et al., 1990; Feltkamp et al., 1993
with or without adjuvants Deres et al., 1989; Lipford et al., 1994
Yasutomi et al., 1993b; Shirai et al., 1994
Zhou et al., 1992
by recycling from the cell surface; and in other subcellu- such as TNFa, IL-1, and LPS (Steinman and Swanson,
1995; Lanzavecchia, 1996). The major APC for the gener-lar organelles belonging to the endocytic system (Xu
and Pierce, 1995). ation of CTL responses are macrophages and dendritic
cells (DC) (Young and Steinman, 1990; Debrick et al.,
1991; Rock et al., 1993; Elbe et al., 1994; Harding andUptake of Exogenous Antigen by APC
To initiate a CTL response, MHC-bound peptides have Song, 1994; Bo¨hm et al., 1995). Macrophages ingest
large particles by phagocytosis, involving cytoskeletalto be presented to naive T cells by professional APC
that express high levels of MHC-I molecules, adhesion elements such as tubulin and actin for the formation
of highly proteolytic phagosomes (Allen and Aderem,receptors, and potent costimulator activity. APC inter-
nalize antigen locally and move to lymphoid tissues in 1996). Macrophages can also collaborate with DC by
degradation and transfer of smaller antigenic particlestwo functionally distinct phases: uptake/transportation
and T cell activation regulated by inflammatory stimuli to these (Nair et al., 1995; Gong et al., 1994).
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Table 2. Processing of Exogenous Antigen for MHC-I Expression In Vitro
Cellular Handling Processing Characteristics
Uptake and leakage to cytosol Cytosolic MHC-I pathwaya Slow and inefficient. Require high Ag
concentrations. Depend on proteasomes,
TAP transporters, chaperones, and Golgi transport.
Uptake, digestion, and secretion At membrane by ‘‘regurgitation’’ Slow and inefficient. Require high Ag concentrations.
Uptake in a vesicular compartment In an ‘‘endosomal-like’’ compartment BFA resistant, TAP independent, and
sensitive to endosomal inhibitors.
Peptide binding to ‘‘empty’’ MHC-I Not required Sensitizes target cells.
a Cytosolic protein can also enter an ‘‘endosomal-like’’ pathway through hsp-mediated uptake (Schirmbeck and Reimann, 1994).
Nonphagocytic uptake of antigen into APC can be pathway as judged by the inhibitory effect of BFA or
proteasomal inhibitors (or both) (Takahashi et al., 1990;either receptor operated or in the fluid phase by pino-
cytosis, macropinocytosis, and phagocytosis (Stein- van Binnendijk et al., 1992; Aggarwal et al., 1990; Aldov-
ini and Young, 1991; Stover et al., 1991, 1993; Schaferman, 1991; Reis e. Sousa et al., 1993; Sallusto et al.,
1995). Macropinocytosis in DC is constitutive and highly et al., 1992; Rock, 1996). Little is presently known about
this “leakage” from phagosomes to the cytosol: whetherefficient and leads to the concentration of internalized
material into intracellular vesicular processing compart- it is an energy-dependent process regulated by specific
transporters, whether it depends on unspecified dam-ments (Lanzavecchia, 1996). A receptor-operated up-
take can either depend on mannose, scavenger-type age to the vesicular membrane, or whether it represents
an important in vivo event. The phagosome to cytosolreceptors (such as DEC-205 in the mouse) or other, less
defined receptors (Pearson, 1996; Manca et al., 1991; transfer process has been demonstrated with internal-
ized toxin, which lacks the capacity to penetrate mem-Ezekowitz et al., 1990; Stahl, 1992; Jiang et al., 1995).
Consequently, a number of different uptake pathways branes but still can enter the cytosol toact on ribosomes
(Reis e. Sousa and Germain, 1995; Norbury et al., 1995;operate in APC with the capacity to handle antigen dif-
ferently: complete degradation, partial degradation and Kovacsovics-Bankowski and Rock, 1995), with fluores-
ceinated dextran and ISCOM-associated protein anti-secretion, partial degradation and leakage to the cytosol
(see below), or uptake into vesicular processing com- gen, and in different intracellular microbial systems (Nor-
bury et al., 1995; Andrews, 1994; Morein et al., 1994).partments. Different uptake mechanisms might also tar-
get the antigen to different processing compartments, There is also evidence for a bidirectional transfer of
peptides and proteins between lysosomes and the cyto-such as the cell membrane, early endosomes, lyso-
somal-like vesicles, or thecytosol. Different peptide rep- sol, including fusion between autophagosomes and ly-
sosomes or hsp-73-mediated antigen transfer (Isenmanertoires for MHC binding and presentation might poten-
tially be generated in these distinct compartments. and Dice, 1989; Dice, 1992; Mortimore and Kadowaki,
1994; Schirmbeck and Reimann, 1994).
Secreted peptides from partially digested antigens inProcessing of Exogenous Antigen for
MHC-I-Restricted Peptide Presentation phagosomes can bind membrane MHC-I by “regurgita-
tion.” These peptides can also bind to MHC-I on “by-Processing has been studied at different levels, includ-
ing target cell recognition and the capacity of cells to stander” cells in the immediate vicinity of the processing
cells (Pfeifer et al., 1993a; Rock, 1996). This has beengenerate CTL in in vitro cultures. Target cell recognition
is a comparatively simple event requiring only short- found with ovalbumin (either present as bacterial fusion
protein or bound to beads) in some studies, but not interm expression of a few presentation-competent tri-
meric complexes to trigger CTL lysis (Christinck et al., others (Pfeifer et al., 1993b; Reis e. Sousa and Germain,
1995; Rock, 1996). It thus remains to be determined1991). Both normal and TAP mutant cells and cell lines
have been used. Pathways have been defined further whether partially digested antigens from phagocytes
can actually be processed for MHC-I presentation byby cellular inhibitors selective for Golgi transport (brefel-
din A [BFA]) or proteasomal activity (lactacystin and the regurgitation process, or whether it is an in vitro
phenomenon that readily happens with fixed cells. Apeptide aldehydes) and those that target endosomal
functions such as vesicular pH, proteolysis, and trans- more likely alternative may be transfer of partially di-
gested antigen into DC through any of the multipleport (Table 2).
Exogenous antigens such as recombinant bacteria, mechanisms these cells can use for internalization of
antigen.bead-coupled or aggregated proteins, or antigens incor-
porated into liposomes or ISCOM particles are internal- Phagocytic processing of exogenous antigens, in
both professional and nonprofessional phagocytes, isized into macrophages by phagocytosis and can enter
different processing pathways for MHC-I-restricted pre- more efficient if the antigen is either coupled or mixed
with beads that by themselves have the capacity tosentation of peptides (Harding and Song, 1994; Kovac-
sovics-Bankowski et al., 1993; Reis e. Sousa et al., 1993; activate phagosomes (Huang et al., 1994; Kovacsovics-
Bankowski et al., 1993; Rock et al., 1993; De Bruijn etPfeifer et al., 1993b; Falo et al., 1995; Bachmann et
al., 1995; Rock, 1996). Some antigens can escape from al., 1995). A closer analysis of phagocytic processing
by Reis e. Sousa and Germain (1995) and Schirmbeckphagosomes into the cytosolic compartment, where
they presumably enter the endogenous processing et al. (1995c), comparing peptide- and bead-associated
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antigens, characterized it as inefficient and related to shown to direct a subset of MHC-I molecules directly
phagocytic overload (“cellular indigestion”). Phagocytic to the endocytic compartment, even if the peptide pre-
processing of many antigens is thus slow, requires high sentation capacity of such chaperoned MHC-I mole-
antigen concentrations, and is potentially risky as it cules has not been determined (Sugita and Brenner,
might involve sensitization of innocent bystander cells. 1995). Glycosylated class I–binding peptides, which
Nonphagocytic processing of exogenous antigens for bind to cells expressing the corresponding restriction
MHC-I-restricted presentation of peptides has been element with high specificity and are easily detected
demonstrated with inactivated virus particles, surface with specific anti-carbohydrate monoclonal antibodies
or core virus-like particles, and glycopeptides (Rock, by fluorescence-activated cell sorting, are readily recy-
1996; Abdel Motal et al., 1993, 1996; Schirmbeck and cled to the cell membrane after internalization. This pro-
Reimann, 1994; Schirmbeck et al., 1995a, 1995c; Zhou cess is blocked by endosomal inhibitors (Abdel Motal
et al., 1995). This pathway is rapid and requires low et al., 1993, 1995a). It is not clear whether peptides are
doses of antigen to elicit a response. It is resistant to recycling on the same class I molecules that are used for
BFA, operates in mutant cells that express no TAP pep- internalization or whether an active peptide exchange
tide transporter activity, and is also blocked by lipophilic occurs in the endosomal compartment. The internaliza-
amines that raise endosomal pH, affect uptake mecha- tion process is, however, important for the formation of
nisms, and inhibit vesicular trafficking. These effects presentation-competent trimeric class I complexes (see
indicate that processing of exogenous antigens for below). The low pH in endosomes may favor peptide
MHC-I expression relies on mechanisms similar to those exchange and the formation of presentation-competent
operating in the MHC-II pathway. There are also addi- complexes, as well as influencing theexpressed peptide
tional similarities, as both MHC-I and MHC-II molecules repertoire. pH is known to influence the spectrum of
recycle between an intracellular compartment and the peptides that bind class I molecules (Stryhn et al., 1996).
cell surface (Yewdell and Bennink, 1992; Wraith and Alternative configurations of MHC-I molecules are ex-
Vessey, 1986; Wraith et al., 1987; Reid and Watts, 1990). pressed on the cell surface, such as stable trimeric com-
In vivo data from a transgenic mouse model suggest a plexes (including b2-microglobulin light chains and anti-
role for recycling of MHC-I in the priming event of CTL genic peptides) or “empty” heavy chains, which are not
responses. Two lines of transgenic mice were con- loaded with peptides and not stably associated with b2-
structed (on a DBA background), one of which ex- microglobulin (Lie et al., 1990, 1991; Matko et al., 1994;
pressed the class I molecule Db in its normal, transmem- Carreno and Hansen, 1994; Smith et al., 1992a, 1992b;
branous, and recycling form and the other of which 1993; Allen et al., 1986; Jackson and Peterson, 1993;
expressed a glycosylphosphatidylinositol (GPI)-linked Jackson et al., 1994). “Empty” MHC-I molecules, stably
form of Db that could not recycle, or at least had a expressed at 378C on the surface of normal and, in
severely reduced capacity to recycle. Only mice that particular, TAP mutant cells, may arise from peptide
expressed the normal, recycling Db molecules, and not or b2-microglobulin dissociation of assembled trimeric
mice that expressed the GPI-linked, nonrecycling form complexes (or both) (Bernabeau et al., 1984; Rock et
of Db molecules, could generate a CTL response against al., 1990, 1991; Schuhmacher et al., 1990; Vitiello et al.,
an immunodominant epitope in the influenza A virus 1990; Kozlowski et al., 1991). Alternatively, empty MHC-I
nucleoprotein after virus infection (Abdel Motal et al., heavy chains may be transported from the ER to the
1995b). cell surface as free heavy chains (Allen et al., 1986).
An endosomal processing compartment would need Chaperone molecules may be involved in the expression
an input of MHC-I molecules that can bind processed of empty MHC-I molecules at the cell surface and in
peptides. MHC-I molecules could be derived by recy-
their recycling through endosomal-like compartments.
cling from the cell surface, from the formation of mem-
A recent report described the heterodimerization of
brane vesicles containing correctly positioned MHC-I
empty Ld molecules with T3-encoded Qa-1 molecules
molecules, or by direct transport from the ER compart-
on the cell surface (Wolf and Cook, 1995). However,ment. Recycling of class I molecules between the cell
surface-expressed empty MHC-I molecules at 378C domembrane and an endosomal compartment has been
not directly bind exogenous peptides, i.e., empty MHC-Idemonstrated in both T cells and macrophages and
molecules are not converted into presentation-compe-shown to exceed the de novo synthesis pathway in
tent trimeric complexes by binding exogenous peptidesterms of membrane expression (Yewdell and Bennink,
(Lie et al., 1990, 1991; Smith et al., 1992a, 1992b, 1993).1992; Reid and Watts, 1990; Dasgupta et al., 1988). The
These empty class I molecules may have to be internal-cytoplasmic tail of MHC-Imolecules contains phosphor-
ized before they can be loaded with antigenic peptidesylation sites that might regulate recycling to allow a
from endocytosed, exogenous antigens and associateselective accumulation of presentation-competent com-
with b2-microglobulin to generate presentation-compe-plexes, although this is hypothetical (Vega and Strom-
tent trimeric complexes. Exogenous 22 nm hepatitis Binger, 1989). Phagocytic vesicles, derived from the
surface antigen (HBsAg) particles are taken up by manyplasma membrane, might contain peptide-receptive
cells and processed in a novel peptide transporter–class I molecules, or newly synthesized class I mole-
independent, endosomal, or lysosomal pathway forcules might bedirectly transported to thesewith the help
class I (Ld)-restricted epitope presentation. Empty Ldof chaperone proteins (De Bruijn et al., 1995). Eventually,
molecules defined by specific monoclonal antibodies,these class I molecules might be transferred to an endo-
which are derived from the cell surface, are involved incytic compartment by vesicular transport. The invariant
chain, used for trafficking of class II molecules, has been presenting antigenic peptides from endocytosed HBsAg
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particles (Schirmbeck and Reimann, 1996). Another spe- processing? Do they generate a spectrum of MHC-I-
cies of empty MHC-I molecules can be artificially in- bound peptides distinct from those generated in the
duced (by low temperature on TAP mutant cells) and cytosolic pathway? Finally, how do MHC-I molecules
loaded with exogenous peptides (Schuhmacher et al., gain access to the endosomal-like compartment, and
1990; Ljunggren et al., 1990; Machold et al., 1995). How- how are trimeric peptide MHC-I–b2-microglobulin com-
ever, these empty MHC-I molecules are thermolabile plexes transported to the cell surface and their mem-
and hence not equivalent to empty forms expressed brane expression regulated?
under physiological conditions. If exogenous antigens are instrumental in priming nor-
Synthetic peptides that have the correct MHC-I bind- mal CTL responses, processing in noncytosolic, vesicu-
ing motif and correspond to known CTL epitopes (usu- lar compartments, distinct from the endogenous classi-
ally 8–12 amino acids long) do not require any pro- cal class I processing pathway, might be important. If
cessing and generate CTL responses in vivo (Alchele et so, it may be relevant to reevaluate the endogenous/
al., 1990; Feltkamp et al., 1993; Yasutomi et al., 1993b; MHC-I and exogenous/MHC-II processing dogma and
Zhou et al., 1992). As discussed above, these probably instead classify pathways in functional terms. In CTL
bind to empty MHC-I molecules in an intracellular pro- activation, induction (by exogenous antigen) and tar-
cessing compartment to form presentation-competent get cell recognition (by endogenous antigen) by class
complexes. The in vivo responses to short, synthetic I–restricted peptide presentation would result from dif-
peptides can be independent of CD41 helper T cells, ferent processing pathways. This is an important issue
as shown with both CD4 knockout mice and anti-CD4- in terms of vaccine development, as these should pri-
treated mice (Zhou et al., 1992b; Fayolle et al., 1996). marily be expressed in the most optimal processing
Studies in TAP knockout mice give further support compartment. If exogenous antigens are of major impor-
for an alternative MHC-I processing pathway. Although tance in generating CTL responses, vaccines based on
these mice have severely reduced MHC-I membrane live, replicating vectors (and nucleic acids) induce their
levels and do not generate virus-specific CTL re- protective effect in a nonviable form. In this transfer
sponses, they can respond to other antigens such as process, from the infected host cell to the professional
alloantigens, tumors, and short peptides representing APC cell, there might be a lesson to be learned in terms
immunodominant epitopes (Ljunggren et al., 1995a,
of formulations for direct uptake into APC cells. The
1995b; van Kaer et al., 1992; Sandberg et al., 1996). The
potent clinical effect of the first human recombinant
inability to generate virus-specific CTL may reflect a
vaccine licensed for clinical use, which was based on
reduced input of MHC-I molecules into the processing
self-assembly of the hepatitis B virus small surface anti-
compartment, since class I heavy chains mostly remain
gen into 22 nm subviral particles, might be a “lesson of
in the ER in these mice as a consequence of the TAP
nature” in this context (Schirmbeck et al., 1996).deficiency. However, other antigens, to which these
mice can respond, might internalize more readily into the
Referencesprocessing compartment and thus efficiently capture
those few MHC-I molecules that have escaped from the
Abdel Motal, U.M., Zhou, X., Joki, A., Siddiqi, A.R., Srinivasa, B.R.,
ER compartment. Stenvall, K., Dahme´n, J., and Jondal, M. (1993). Eur. J. Immunol. 23,
3224–3229.
Conclusions Abdel Motal, U.M., Berg, L., Bengtsson, M., Dahme´n, J., Kihlberg,
A number of different modified exogenous protein anti- J., Magnusson, G., Nilsson, U., and Jondal, M. (1995a). J. Immunol.
gens can efficiently prime CTL responses. The biological Meth. 188, 21–31.
significance of this for priming of normal CTL responses Abdel Motal, U.M., Sentman,C.L., Zhou, X., Robinson, P.J., Dahme´n,
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presentation seems an attractive possibility to bypass Abdel Motal, U.M., Berg, L., Rose´n, A., Bengtsson, M., Thorpe, C.J.,
the necessity that all foreign antigens have to be trans- Kihlberg, J., Dahme´n, J., Magnusson, G., Karlsson, K.-A., and Jon-
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wood, 1994). Another scenario for a virus-specific CTL Aldovini, A., and Young, R.A. (1991). Nature 351, 479–482.
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